FR3087650B1 - Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer - Google Patents

Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer Download PDF

Info

Publication number
FR3087650B1
FR3087650B1 FR1860114A FR1860114A FR3087650B1 FR 3087650 B1 FR3087650 B1 FR 3087650B1 FR 1860114 A FR1860114 A FR 1860114A FR 1860114 A FR1860114 A FR 1860114A FR 3087650 B1 FR3087650 B1 FR 3087650B1
Authority
FR
France
Prior art keywords
fad
cancer
prevention
treatment
adenine dinucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1860114A
Other languages
English (en)
Other versions
FR3087650A1 (fr
Inventor
Didier Paleni
Jolanda Spadavecchia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Even
Original Assignee
Bio Even
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Even filed Critical Bio Even
Priority to FR1860114A priority Critical patent/FR3087650B1/fr
Priority to PCT/EP2019/079693 priority patent/WO2020089310A1/fr
Priority to CN201980068982.9A priority patent/CN112955152A/zh
Priority to EP19804641.9A priority patent/EP3873485A1/fr
Priority to US17/289,221 priority patent/US20220008451A1/en
Publication of FR3087650A1 publication Critical patent/FR3087650A1/fr
Priority to PCT/FR2020/000199 priority patent/WO2021084166A1/fr
Application granted granted Critical
Publication of FR3087650B1 publication Critical patent/FR3087650B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01009—Thioredoxin-disulfide reductase (1.8.1.9), i.e. thioredoxin-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds

Abstract

L'invention concerne la Flavine Adénine Dinucléotide (FAD) pour son utilisation pour la prévention et/ou le traitement de cancer. Avantageusement, la FAD est au moins partiellement encapsulée dans un particule avec un vecteur pour améliorer son absorption et sa distribution tout en limitant sa destruction notamment par des hydrolases sanguines. L'invention appartient au domaine pharmaceutique et plus spécifiquement l'oncologie ou la cancérologie.
FR1860114A 2018-10-31 2018-10-31 Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer Active FR3087650B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1860114A FR3087650B1 (fr) 2018-10-31 2018-10-31 Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
PCT/EP2019/079693 WO2020089310A1 (fr) 2018-10-31 2019-10-30 Flavine adénine dinucléotide (fad) pour son utilisation pour la prévention et/ou le traitement de cancer
CN201980068982.9A CN112955152A (zh) 2018-10-31 2019-10-30 用于预防和/或治疗癌症的黄素腺嘌呤二核苷酸
EP19804641.9A EP3873485A1 (fr) 2018-10-31 2019-10-30 Flavine adénine dinucléotide (fad) pour son utilisation pour la prévention et/ou le traitement de cancer
US17/289,221 US20220008451A1 (en) 2018-10-31 2019-10-31 Flavin adenine dinucleotide (fad) for use in the prevention and/or treatment of cancer
PCT/FR2020/000199 WO2021084166A1 (fr) 2018-10-31 2020-07-06 Nanostructure d'or comprenant des enzymes et des agents antioxydants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1860114A FR3087650B1 (fr) 2018-10-31 2018-10-31 Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer

Publications (2)

Publication Number Publication Date
FR3087650A1 FR3087650A1 (fr) 2020-05-01
FR3087650B1 true FR3087650B1 (fr) 2021-01-29

Family

ID=65861386

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1860114A Active FR3087650B1 (fr) 2018-10-31 2018-10-31 Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer

Country Status (5)

Country Link
US (1) US20220008451A1 (fr)
EP (1) EP3873485A1 (fr)
CN (1) CN112955152A (fr)
FR (1) FR3087650B1 (fr)
WO (2) WO2020089310A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023164224A1 (fr) * 2022-02-28 2023-08-31 The Board Of Trustees Of The Leland Stanford Junior University Nanoagrégats fonctionnalisés et leur utilisation dans le traitement d'infections bactériennes
KR102658967B1 (ko) * 2023-07-03 2024-04-19 주식회사 렛서 인공지능 기반 솔루션을 제공하기 위한 방법, 전자 장치, 및 시스템

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1079165A (en) 1964-06-24 1967-08-16 Kyowa Hakko Kogyo Kk Process for producing flavin-adenine dinucleotide
DE1570027C3 (de) 1964-06-24 1975-03-06 Kyowa Hakko Kogyo Co. Ltd., Tokio Verfahren zur fermentativen Herstellung von Flavin-adenin-dinucleotid
US4255566A (en) 1980-02-19 1981-03-10 Miles Laboratories Flavin adenine dinucleotide derivatives and labeled conjugates prepared therefrom
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
DE69124223T2 (de) * 1990-02-05 1997-04-30 Lifescience Corp Vitamine und mineralien enthaltende nahrungszusätze
JPH07149655A (ja) * 1993-11-29 1995-06-13 Ajinomoto Co Inc Ｎｏ合成酵素活性化剤
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
EP0938597B1 (fr) 1996-09-06 2003-08-20 Obducat Aktiebolag Procede de gravure anisotrope de structures dans des materiaux conducteurs
WO1998022461A1 (fr) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e et f, mode de preparation et application comme agents cytostatiques et phytosanitaires
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
IL138113A0 (en) 1998-02-25 2001-10-31 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto and analogues thereof
IL143069A0 (en) 1998-11-20 2002-04-21 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
US8802161B2 (en) * 2003-08-02 2014-08-12 Florida Agricultural And Mechanical University Herbal composition and method of use for the treatment of cancer
EP2535352B1 (fr) 2011-06-16 2015-08-12 Universitätsklinikum Freiburg Composition pharmaceutique dotée d'anticorps contre la catalase et la superoxyde dismutase pour le traitement des tumeurs
WO2018148930A1 (fr) * 2017-02-17 2018-08-23 纯菁生物科技（美国）有限公司 Utilisation de nadh ou fadh2 dans une intervention nutritionnelle pour un patient atteint d'un cancer

Also Published As

Publication number Publication date
EP3873485A1 (fr) 2021-09-08
WO2021084166A1 (fr) 2021-05-06
CN112955152A (zh) 2021-06-11
FR3087650A1 (fr) 2020-05-01
US20220008451A1 (en) 2022-01-13
WO2020089310A1 (fr) 2020-05-07

Similar Documents

Publication Publication Date Title
MA44549A1 (fr) Agents immunorègulateurs
FR3087650B1 (fr) Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MA39767B1 (fr) Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec
MA42160A (fr) Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii
ES2068166T3 (es) Taxano con actividad antitumoral.
WO2021174107A8 (fr) Variants d'ace2 solubles et utilisations associées
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
FR3061856B1 (fr) Utilisations therapeutiques d'une poudre d'insectes
EA201491081A1 (ru) Композиции и способы для лечения заболеваний и расстройств печени
HK1102702A1 (en) Anti-viral uses of borinic acid complexes
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
TN2014000195A1 (fr) 2-thiopyrimidinones
WO2021203103A3 (fr) Polymorphismes du récepteur ace2 et sensibilité variable aux sras-cov-2, procédés de diagnostic et de traitement
Law et al. Photodynamic therapy with curcumin for combating SARS-CoV-2
MX2021000505A (es) Metodos para tratar cancer con virus de mixoma que expresa tnf.
EA201590796A1 (ru) Фибринолитические композиции, включающие бромелаин и наттокиназу, для предотвращения и лечения флеботромботических состояний
MA38009A1 (fr) Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
FR3062063B1 (fr) Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
FR3046728B1 (fr) Nouvelles nanoparticules d'organosilice mesoporeuses, leur methode de preparation et leurs utilisations.
TR201902785T4 (tr) Oksidatif stresi azaltmak için alfa-ketoglutarik asit ve 5-hidroksi-metilfurfural kullanımı.
WO2023019100A3 (fr) Nouvelles méthodes thérapeutiques d'utilisation de muropeptides de peptidoglycanes pour favoriser l'activité de l'atp synthase ainsi que l'homéostasie et le développement mitochondriaux
MX2022011692A (es) Tecnologias para prevenir o tratar infecciones.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200501

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6